医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Orum Therapeutics Appoints Jae Won Kim Chief Financial Officer

2021年05月26日 PM09:00
このエントリーをはてなブックマークに追加


 

BOSTON & DAEJEON, South Korea

Orum Therapeutics, a global biotech company pioneering the development technologies for precision delivery of targeted protein degraders to treat cancer, today announced the appointment of Jae Won Kim as Chief Financial Officer.

“We are excited to welcome Jae Won to the Orum team,” said Sung Joo Lee, Ph.D., Founder and CEO of Orum Therapeutics. “Jae Won brings deep expertise in healthcare investment banking with a broad range of finance and deal experience. Her appointment comes at an important juncture for the company, and she will play a pivotal role in driving sustainable long-term growth, supporting the company to ascend to the next level.”

“I’m impressed by Orum’s differentiated platform that combines targeted protein degradation with the precision of antibody drug conjugate technology,” said Ms. Kim. “Orum has great potential for developing innovative, first-in-class targeted protein degradation therapeutics that can be applied to many different diseases driven by targets that are currently considered undruggable.”

Prior to joining Orum, Jae Won Kim served as a Director on the Citi Healthcare Investment Banking team based in New York. She spent more than 10 years in the financial industry, where she advised healthcare companies on strategic transactions and led various financings. She completed a joint JD-MBA program at Northwestern University and earned a BA in English Literature and Business Administration from Korea University. She is an attorney-at-law in the state of New York.

About Orum Therapeutics

Orum Therapeutics is pioneering the development of technologies for precision delivery of targeted protein degraders for the treatment of cancer. The company’s neoDegraders are novel, proprietary payloads for targeted protein degradation and its Antibody neoDegrader Conjugate (AnDC) platform generates first-in-class antibody drug conjugates. The first therapeutic candidates from the AnDC platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Cambridge, Massachusetts, U.S., and Daejeon, South Korea. For more information, visit www.orumrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005061/en/

CONTACT

Corporate: Sung Joo Lee, Ph.D., Founder and CEO, Orum Therapeutics, +82-42-716-3030, contact@orumrx.com

Media: Jessica Yingling, Ph.D., President, Little Dog Communications Inc., +1-858-344-8091, jessica@litldog.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
  • DKT International Implements Traditional and New Forms of Marketing in Africa, South America, and Southeast Asia to Expand Access to Contraceptives
  • オルガノンが計画外妊娠をめぐり世界規模の対話の喚起を目指す
  • IHMA Opens Microbiology Reference Laboratory in Shanghai, China to Further Support Global Anti-Infective Product Discovery and Development
  • Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development